ReviewAdvances in experimental medicine and biology2026
Diagnostic Constructs of Major Depression in DSM-5: Current Critiques and Future Directions.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostic frameworks for major depression in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and DSM-5 revision process (DSM-5-TR) have been largely defined by the significant transition from a categorical approach to a hybrid concept incorporating dimensional concepts. The main updates in the DSM-5 diagnostic framework of major depression are the addition of hopelessness as a descriptor for depressed mood, the removal of the bereavement exclusion, and the introduction of specifiers, including "with anxious distress," "with mixed features," and "peripartum onset." The DSM-5-TR has newly added the depression-related diagnostic entities, including unspecified mood disorder, persistent grief disorder, suicidal behavior, nonsuicidal self-injury, and hikikomori. However, the symptom-based operation criteria for major depression remain challenging, including high clinical heterogeneity, high comorbidity, transdiagnostic nature of overlapping symptoms, and lack of integration with neurobiological markers. To overcome these limitations, the etiology-based classifications with integrating biomarkers and the digital phenotyping with ecological momentary assessments have been suggested as diagnostic practices in the level of research. The neuroinflammatory biomarkers and brain imaging have been regarded as a promising tool, but their issues regarding reproducibility and cost remain challenging in clinical applications. In addition, the digital tools with big data, wearable devices, and natural language processing may enhance the diagnostic precision, despite their issues of ethics and standardizations. Future diagnostic frameworks can be discussed in terms of personalized and biologically informed approaches in response to address the complexities of clinical practice. Integrating innovative methods with symptom-based diagnostic systems may contribute to more accurate and effective diagnostic classifications of major depression.
Indexed as
Identifiers
42036558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.